Причины развития и методы коррекции посттрансплантационного сахарного диабета
https://doi.org/10.23873/2074-0506-2017-9-4-335-349
Аннотация
Обзор посвящен проблеме посттрансплантационного сахарного диабета как одного из осложнений после трансплантации почки. Проведен анализ клинических и экспериментальных исследований, описаны механизмы влияния иммуносупрессивных препаратов на углеводный обмен, а также факторы риска посттрансплантационного сахарного диабета и его осложнений, основные препараты, применяемые для коррекции углеводного обмена, и их механизмы действия.
Об авторах
К. Е. Лазарева
ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»;
Кафедра трансплантологии и искусственных органов ФГБОУ ВО МГМСУ
им. А.И. Евдокимова МЗ РФ
Россия
Россия
канд. мед. наук, врач-эндокринолог отделения трансплантации почки и поджелудочной железы НИИ скорой помощи им. Н.В. Склифосовского
Москва
О. Н. Ржевская
ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»;
Кафедра трансплантологии и искусственных органов ФГБОУ ВО МГМСУ
им. А.И. Евдокимова МЗ РФ
Россия
Москва
Россия
Москва
Н. В. Загородникова
ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»
Россия
Москва
Россия
Москва
Список литературы
1. Хубутия М.Ш., Ржевская О.Н., Лазарева К.Е. Нарушение метаболизма глюкозы после трансплантации органов. Трансплантология 2009.(2):9–14.
2. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3–SS24. PMID:12775942 DOI:10.1097/01.TP.0000069952.49242.3E
3. Wilkinson A., Davidson J., Dotta F., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin. Transplant. 2005;19(3):291–298. PMID:15877787 DOI:10.1111/j.1399-0012.2005.00359.x
4. Sharif A. Hecking M., de Vries AP., et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am. J. Transplant. 2014;14(9):1992–2000. PMID:25307034 DOI:10.1111/ajt.12850
5. Cosio F.G., Kudva Y., van der Velde M., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67(6):2415–2421. PMID:15882287 DOI:10.1111/j.1523-1755.2005.00349.x
6. Hecking M., Kainz A., Werzowa J., et al. Glucose metabolism after renal transplantation. Diabetes Care. 2013;36(9):2763–2771. PMID:23656979 DOI:10.2337/dc12-2441
7. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J. Transplant. 2007;7(6):1506–1514. PMID:17359512 DOI:10.1111/j.1600-6143.2007.01749.x
8. Chakkera H.A., Weil E.J., Pham P.T., et al. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36(10):1406–1412. PMID:24065856
9. Hornum M., Jørgensen K.A., Hansen J.M., et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin. J. Am. Soc. Nephrol. 2010;5(4):709–716. PMID:20167685 DOI:10.2215/CJN.05360709
10. Voytovich M.H., Simonsen C., Jenssen T., et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol. Dial. Transplant. 2005;20(2):413–418. PMID:15615809, DOI:10.1093/ndt/gfh641
11. Werzowa J., Hecking M., Haidinger M., et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebocontrolled clinical trial. Transplantation. 2013;95(3):456–462. PMID:23380864 DOI:10.1097/TP.0b013e318276a20e
12. Delaunay F., Khan A., Cintra A., et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest. 1997;1009(8):2094–2098. PMID:9329975 DOI:10.1172/JCI119743
13. Andrews R.C., Walker B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin. Sci. (Lond.). 1999;96(5):513–523. PMID:10209084
14. Hjelmesaeth J., Hagen L.T., Asberg A., et al. The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. Nephrol. Dial. Transplant. 2007;22(6):1743–1749. PMID:17299003 DOI:10.1093/ndt/gfl820
15. Gunnarsson R., Lundgren G., Magnusson G., et al. Steroid diabetes-A sign of overtreatment with steroids in the renal graft recipient? Scand. J. Urol. Nephrol. Suppl. 1980;54:135–138. PMID:7013032
16. Hjelmesaeth J., Hartmann A., Kofstad J., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64(7):979–983. PMID:9381545
17. Yang W.C., Chen Y.S, Hsieh W.C., et al. Post-transplant Diabetes Mellitus in Renal Transplant Recipients – Experience in Buddhist Tzu Chi General Hospital. Tzu. Chi. Med. J. 2006;18(3):185–191.
18. Sumrani N.B., Delaney V., Ding Z.K., et al. Diabetes mellitus after renal transplantation in the cyclosporin era: an analysis of risk factors. Transplantation. 1991;51(2):343–347. PMID:1994525
19. Boudreaux J.P., McHugh L., Canafax D.M., et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987;44(3):376–381. PMID:3307061
20. Von Kiparski A., Fred D., Uhlschmid G., et al. Post-transplant diabetes mellitus in renal allograft recipients: A matchedpair control study. Nephrol. Dial. Transplant. 1990;5(3):220–225. PMID:2113651
21. Wahlstrom H.E., Akimoto R., Endres D., et al. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of shortterm cyclosporine treatment. Transplantation. 1992;53(6):1190–1195. PMID:1604471
22. Gillison S.L., Bartlett S.T., Curry D.L. Inhibition by cyclosporine of insulin secretion – a beta cell-specific alteration of islet tissue function. Transplantation. 1991;52(5):890–895. PMID:1683035
23. Cosio F.G., Hickson L.J., Griffin M.D., et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am. J. Transplant. 2008;8(3):593–599. PMID:18294155 DOI:10.1111/j.1600-6143.2007.02101.x
24. Hricik D.E., Bartucci M.R., Moir E.J., et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 1991;51(2):374–377. PMID:1994531
25. Cosio F.G., Pesavento T.E., Kim S., et al. Patient survival after renal transplantation: IV. Impact of posttransplant diabetes. Kidney Int. 2002;62(4):1440–1446. PMID:12234317 DOI:10.1111/j.1523-1755.2002.kid582.x
26. Revanur V.K., Jardine A.G., Kingsmore D.B., et al. Influence of diabetes mellitus on patients and graft survival in recipients of kidney transplantation. Clin. Transplant. 2001;15(2):89–94. PMID:11264633
27. Thomas M.C., Mathew P.H., Russ G.R., et al. Early perioperative glycemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72(7):1321–1324. PMID:11602863
28. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N. Engl. J. Med. 1994;330(13):877–884. PMID:8114857 DOI:10.1056/NEJM199403313301301
29. Noble N.A., Border W.A. Angiotensin II in renal fibrosis. Should TGFbeta rather than blood pressure be the therapeutic target? Semin Nephrol. 1997;17(5):455–466. PMID:9316214
30. Sumrani N.B., Delaney V., Ding Z., et al. Diabetes mellitus after renal transplantation in the cyclosporine era : an analysis of risk factors. Transplantation. 1991;51(2):343–347. PMID:1994525
31. Miles A.M., Sumrani N., Horowitz R., et al. Diabetes mellitus after renal transplantation. Transplantation. 1998;65(3):380–384. PMID:9484755
32. Lanerolle R.D., de Abrew K., Fernando D.J., Sheriff M.H. Post-renal transplant diabetes in Sri Lanka. Transplant. Proc. 1996;28(10):1945–1947. PMID:8658956
33. Vesco L., Busson M., Bedrossian J., et al. Diabetes mellitus after renal transplantation. Transplantation. 1996;61(10):1475–1478. PMID:8633374
34. Raine A.E.G. Cardiovascular complications after renal transplantation. In: ed. Morris P.J. Kidney Transplantation: Principles and Practice. Philadelphia, PA, Saunders, 1988: 575–601.
35. Schneider D.J., Nordt T.K., Sobel B.E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes. 1993;42(1):1–7. PMID:8420806
36. Gruessner R.W. Tacrolimus in pancreas transplantation: A multi-center analysis. Tacrolimus Pancreas Study Group. Clin. Transplant. 1997;11(4):299–312. PMID:16298658 DOI:10.1016/j.transproceed.2005.09.020
37. Von Kiparsky A., Frei D., Uhlschmid G., et al. Post-transplant diabetes mellitus in renal allograft recipients: a matched pair control study. Nephrol. Dial. Transplant. 1990;5(3):220–225. PMID:2113651
38. Chiu M.Y., Sprague S.M., Bruce D.S., et al. Analysis of fracture prevalence in kidney pancreas allograft recipients. J. Am. Soc. Nephrol. 1998;9(4):677–683. PMID:9555671
39. Marchetti P. Strategies for risk reduction and management of posttransplant diabetes mellitus. Transplant. Proc. 2001;33(5A Suppl):S27–31. PMID:11498202
40. Roumie C.L., Hung A.M., Greevy R.A., et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann. Intern. Med. 2012;157(9):601–610. PMID:2312885
41. Thule P.M., Umpierrez G. Sulfonylureas: a new look at old therapy. Curr. Diab. Rep. 2014;14(4):473. PMID:24563333 DOI:10.1007/s11892-014-0473-5
42. Mocanu M.M., Maddock H.L., Baxter G.F., et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103(25):3111–3116. PMID:11425777
43. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–372. PMID:11790216
44. Turk T., Pietruck F., Dolff S., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am. J. Transplant. 2006;6(4):842–846. PMID:16539642 DOI:10.1111/j.1600-6143.2006.01250.x
45. Voytovich M.H., Haukereid C., Hjelmesaeth J., et al. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. Clin. Transplant. 2007;21(2):246–251. PMID:17425753 DOI:10.1111/j.1399-0012.2006.00634.x
46. Cusi K., Consoli A., DeFronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1996;81(11):4059–4067. PMID:8923861 DOI:10.1210/jcem.81.11.8923861
47. Kolata G.B. The phenformin ban: is the drug an imminent hazard? Science. 1979;203(4385):1094–1096. PMID:424735
48. Shaw J.S., Wilmot R.L., Kilpatrick E.S. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet. Med. 2007;24(10):1160–1163. PMID:17672860 DOI:10.1111/j.1464-5491.2007.02221.x
49. Kurian B., Joshi, R., Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14(8):979–984. PMID:19095596, DOI:10.4158/EP.14.8.979
50. Hecking M., Werzowa J., Haidinger M., et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol. Dial. Transplant. 2013;28(3):550–566. PMID:23328712 DOI:10.1093/ndt/gfs583
51. Sharif A. Should metformin be our antiglycemic agent of choice posttransplantation? Am. J. Transplant. 2011;11(7):1376–1381. PMID:21564529 DOI:10.1111/j.1600-6143.2011.03550.x
52. Jenssen T., Hartmann A. Emer ging treatments for post-transplantation diabetes mellitus. Nat. Rev. Nephrol. 2015;11(8):465-477. PMID:25917553 DOI:10.1038/nrneph.2015.59
53. Bajaj M., Suraamornkul S., Pratipanawatr T., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52(6):1364–1370. PMID:12765945
54. Watkins P.B. Idiosyncratic liver injury: challenges and approaches. Toxicol. Pathol. 2005;33(1):1–5. PMID:15805049 DOI:10.1080/01926230590888306
55. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007;356(24):2457–2471. PMID:17517853 DOI:10.1056/NEJMoa072761
56. Luther P., Baldwin D.Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am. J. Transplant. 2004;49(12):2135–2138. PMID:15575920 DOI:10.1111/j.1600-6143.2004.00613.x
57. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705. PMID:17098089 DOI:10.1016/S0140-6736(06)69705-5
58. Haidinger M., Werzowa J., Hecking M., et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation- a randomized, double-blind, placebo-controlled trial. Am. J. Transplant. 2014;14(1):115–123. PMID:24279801
59. Lane J.T., Odegaard D.E., Haire C.E., et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011;92(10):e56–e57. PMID:22067216 DOI:10.1097/TP.0b013e3182347ea4
60. Strom Halden T.A., Asberg A., Vik K., et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol. Dial. Transplant. 2014;29(4):926–933. PMID:24452849 DOI:10.1093/ndt/gft536
61. Kaakeh Y., Kanjee S., Boone K., Sutton J. Liraglutide-induced acute kidney injury. Pharmacotherapy. 2012;32(1):e7–e11. PMID:22392833 DOI:10.1002/PHAR.1014
62. Weise W.J., Sivanandy M.S., Block C.A., Comi R.J. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32(2):e22–e23. PMID:19171732 DOI:10.2337/dc08-1309
63. Nauck M.A., Del Prato S., DuránGarcía S. et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes. Metab. 2014;16(11):1111–1120. PMID:24919526 DOI:10.1111/dom.12327
64. Yale J.F. Bakris G., Cariou B., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes. Metab. 2014;16(10):1016–1027. PMID:24965700 DOI:10.1111/dom.12348
65. Kohan D.E., Fioretto P., Tang W., List J.F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–971. PMID:24067431 DOI:10.1038/ki.2013.356
66. Hornum M., Lindahl J.P., von ZurMuhlen B., et al. Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: a position statement from the Nordic Transplantation Societies. Transpl. Int. 2013;26(11):1049–1060. PMID:23634804 DOI:10.1111/tri.12112
67. Yates C. J., Fourlanos S., Hjelmesaeth J., et al. New-onset diabetes after kidney transplantation-changes and challenges. Am. J. Transplant. 2012;12(4):820–828. PMID:22123607 DOI:10.1111/j.1600-6143.2011.03855.x
Рецензия
Для цитирования:
Лазарева К.Е., Ржевская О.Н., Загородникова Н.В. Причины развития и методы коррекции посттрансплантационного сахарного диабета. Трансплантология. 2017;9(4):335-349. https://doi.org/10.23873/2074-0506-2017-9-4-335-349
For citation:
Lasareva K.E., Rzhevskaya O.N., Zagorodnikova N.V. The causes of development and methods of correction of post-transplant diabetes mellitus. Transplantologiya. The Russian Journal of Transplantation. 2017;9(4):335-349. (In Russ.) https://doi.org/10.23873/2074-0506-2017-9-4-335-349
Просмотров:
1039
Послать статью по эл. почте 